Policy & Regulation
MabSpace Doses First Subject in Phase 1 Trial of 2nd Generation PD-L1 Antibody
17 April 2018 - - Hong Kong, China-based global biotechnology company MabSpace Biosciences has dosed the first subject in a Phase 1 clinical study of MSB2311 for the treatment of advanced solid tumors, the company said.
MSB2311 is a 2nd generation PD-L1 antibody with a unique pH-dependent antigen binding property that enables intra-tumor recycling and potentiates tumor penetration.
It is the first clinical asset generated by MabSpace's proprietary immune tolerance breaking technology platform.
This study, MSB2311-CSP-001, is a first-in-human, open-label, Phase 1 dose-escalation study of MSB2311, a humanized anti-PD-L1 monoclonal antibody in patients with advanced solid tumors.
A separate China Phase 1 study with several disease expansion cohorts to evaluate preliminary efficacy is at the final stage of regulatory review, and if approved, is expected to be initiated soon.
MabSpace Biosciences specializes in discovering and developing innovative antibody therapeutics using its proprietary immune tolerance breaking technology platform.
The company has built a pipeline in immune-oncology, ophthalmology, and nephrology. It is headquartered in Hong Kong, with a fully-integrated antibody discovery and development facility in Biobay, Suzhou Industrial Park, China.


Related Headlines